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Bio-availability of three formulations
of glibenclamide
8.H.MEYER, F.G.MULLER, H.G.LUUS, H.G.ECKERT
Summary
Eighteen healthy men participated in a double-blind, random-
ised, crossover study to compare the bio-availability of three
5 mg formulations of glibenclamide. The products compared
were Daonil (Hoechst), Glycomin (Lennon) and Melix
(Lagamed). Volunteers received a continuous intravenous
infusion of glucose at a rate of 0,25 g/kg/h for 10 hours. Two
hours after commencement of this infusion medication was
given orally with 200 ml of a 10% (m/v) glucose solution. The
subjects also drank 200 ml of the glucose solution hourly for
5 hours after medication. Blood samples were taken up to 22
hours after medication for radio-immunoassay of glibencla-
mide as well as for measurement of glucose concentrations.
The following kinetic variables were calculated; maximum
concentration, time to maximum concentration, terminal half-
life, areas under the serum concentration-time curves, relative
total clearance, total mean time and relative volume of distri-
bution. Daonil and Glycomin were bio-equivalent, but impor-
tant differences were demonstrated between these two
formulations and Melix. This study method necessitates close
surveillance of volunteers in order to detect and treat hypo-
glycaemia.
S AIr Med J 1989; 76: 146-147.
Glibenclamide belongs to the sulphonylurea group of oral
hypoglycaemic agents, lowering blood glucose by stimulating
the secretion of insulin from the {3-ceJls of the pancreatic
islets.'
Glibenclamide is readily absorbed from the gastro-intestinal
tract. It is excreted infaeces and, as metabolites;in urine and
is bound to plasma proteins to the extent of 99%. Peak serum
concentrations are reached in 4 hours. 2
Subjects and methods
Eighteen healthy men (aged between 18 years and 36 years;
weight between 65 kg and 94 kg) were enrolled to participate
in a double-blind, randomised, cross-over study to compare
the bio-availability of three formulations of 5 mg glibenclamide
tablets: Daonil (Hoechst; batch No. 339 El), Glycomin
(Lennon; batch No. M816320) and Melix (Lagamed; batch
No. 87394). The subjects were randomly allotted to the treat-
ments. Each subject received each treatment once and the trial
periods were separated by a drug-free interval of 7 days.
Volunteers had to be normal on physical examination and
their haematological, clinical chemistry, urinalysis and electro-
cardiographic test results had to be satisfactory in order to be
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included in the study. Volunteers refrained from taking any
medication, alcohol or caffeine and from participation in stre-
nuous exercise as from I week before commencement of the
study until its conclusion. On profile days, food and fluid
intake were standardised in order to minimise intra- and inter-
individual variation.
The study was carried out in conformance with the recom-
mendations for clinical trials in man, as set out in the Declara-
tion of Helsinki (Venice Amendment, 1983) and permission
was obtained from the Ethics Committee of the University of
the Orange Free State. Each volunteer signed an informed
consent form.
On the mornings of profile days, volunteers reported to the
clinic after an overnight fast. Indwelling venous cannulas were
positioned, one in each arm, and subjects received a continuous
intravenous infusion of glucose at a rate of 0,25 g/kg/h for 10
hours. This was administered as a 20% (m/v) intravenous
solution. Two hours after commencement of the glucose infu-
sion the appropriate formulation of glibenclamide was admini-
stered orally with 200 ml of a 10% (m/v) solution of glucose.3
After medication they drank 200 ml of this solution hourly on
the hour for 5 hours. Food intake was not permitted until 8
hours after medication when a standardised meal was served.
They remained in a recumbent position for 10 hours.
Blood samples for glibenclamide assay were taken before
medication and at 0,5, I, 1,5, 2, 2,5, 3, 3,5, 4, 4,5, 5, 6, 7, 8,
10, 12,5 and 22 hours after medication, and immediately
centrifuged and stored at -20°C pending assay. A radio-
immune method was used to measure serum glibenclamide
concentrations.4
Plasma glucose values were determined for each of the
blood specimens. If symptoms of hypoglycaemia occurred,
additional glucose was given intravenously.
Results










Fig. 1. Serum glibenclamide concentrations for Daonil --,lI,X--
Glycomin -----r"-----; and Melix --8 --.
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TABLE I. MEAN ± SD VALUES OF PHARMACOKINETIC
VARIABLES
C:nu = maximum concentration; TI'IU :;;;; time to maximum concentration; T
1
terminal half-life; AUC (0 - 12,5 h) = area under the curve for the period 0 - 2,5
hours; AUC = total area under the curve; Cl-tot/f = relative total clearance; MT-






























TABLE Ill. FREQUENCY FOR TIME TO MAXIMUM
CONCENTRATION
glycaemia. It is imperative that if this method of glucose
administration is used in studies of this nature, volunteers are
closely monitored in order that hypoglycaemia is recognised
and treated.
Because differences of less than 20% are generally considered
clinically irrelevant in bio-equivalence studies, it follows from
our results that Glycomin may be considered bio-equivalent to
Daonil. The probabilities that the true ratios with respect to
Cm•x and AUC are within bio-equivalence ranges of 80 - 120%
are very high at 0,95 and 0,98 respectively. However, the
results in respect of the comparison between Melix and Daonil
reveal that they cannot be considered bio-equivalent. The
upper limits of confidence for the ratio Melix/Daonil are 84%
and 90% for Cm.x and AUC. This means that, at its very best,
the mean Cm•x and AUC of Melix are only 84% and 90% of
that of Daonil but can also be as low as 59% and 58%
respectively. The probability that the true ratios with respect
to Cm•xand AUC are within the bio-equivalence range of 80 -
120% is very low at only 0,08 and 0,19 respectively. It is
therefore clear that Melix cannot be considered bio-equivalent
to Daonil with respect to the extent of absorption as measured
by AUC. The fact that the two products also differed with
respect to Cm.x is probably due to differences in the extent of
absorption rather than the difference in the rate of absorption.
In view of the differences in Cm•x and AUC values Melix can
likewise not be considered bio-equivalent to Glycomin.
From a clinical point of view, it may therefore be stated
that, according to the results of this study, Daonil and Gly-
comin may be expected to be equally efficacious in the manage-















Cmu (ng/ml) 156±65 168 ± 61 112 ± 50
T~ (h) 4,3 ± 1,5 4,2±2,0 4,9± 1,2
Tmu (h) 3,6 ± 1,4 4,1±1,4 4,O±2,1
AUC (0-12,5 h)
(ng/h/ml) 779±451 781 ±388 560±247
AUC (ng/h/ml) 937±702 912±490 690±333
CI-totlf (mllmin) 112± 46 106± 33 139± 46
MT-vsys (h) 7,1 ± 1,9 7,3±2,2 8,O± 1,8
V-syslf (I) 47±29 44±16 64±18
Cm..
AUC
The pharmacokinetic variables are reflected in Table 1. The
time to maximum concentration (Tm.x) and the maximum
concentration (Cm• x) values were determined by inspection,
whereas all the other pharmacokinetic variables were calculated
by means of standard non-eompartmental methods.
Statistical analysis
The variables Cm•x and AUC were subjected to an analysis
of variance with subject, treatment and period as the main
effects. Ninety-five per cent conventional confidence intervals
were constructed for the ratio 'test reference' (expressed as a
percentage) for each variable (Table Il). The interpretation of
the confidence interval for Glycomin/Daonil, for example, is
that the true mean Cm• x of Glycomin lies (with 95% certainty)
between 5% below and 21 % above that of Daonil.
A frequency table is provided for values of T m.. (Table Ill).
Symptoms associated with hypoglycaemia were observed in
12 subjects after medication with Daonil, in 11 after medication
with Glycomin and in 4 after medication with Melix and were
treated with additional intravenous glucose,
*Significant difference.
Discussion and conclusion
No serious side-effects were observed, although several of the
volunteers experienced unpleasant sympto~s owing to hypo-
I. Lamer J. Insulin and oral hypoglycemic drugs. In: Goodman ALS, Good-
man LS, Rail TW, Murad F, eds. The Pharmacologic Basis of Therapeurics.
7th ed. New York: Macmillan. 1985: 1490-1516.
2. Reynolds EF ed. MaTlindale: The EXlra Phannacopoeia. 28th ed. London:
The Pharmaceutical Press, 1982: 843-861.
3. Blume H, Ali SL, Stenshorn G, Stiiber W, Siewerr M. Zur Bioverfiigbarkeit
und pharmakodynamischen Aktivitat hande1siiblichet Glibenk1amid-Feni-
garzneimirrel. Pharm Zlg 1985; 130: 2605-2610.
4. Hepmer W, Badian M, Baendner S el al. A radioimmunoassay far determina-
tion of glibenclamide and other sulphany1ureas. Phanllaceuc Res 1984; 5:
215-220.
